ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire/ — STB Lifesaving
Technologies® today announced that it has been awarded a
Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S.
government in the amount of $244,479.
The Qualifying Therapeutic Discovery Project was included in the
Health Care Reform Bill to foster medical, life science, and
biological innovation in the U.S., and the grant was based upon
research expenditures for its lead product, the Fibrin
Adhesive STat®, or FAST® dressing.
STB® has conducted successful animal studies for the FAST®
dressing with both military and commercial partners and is
further supported by published data from the American Red Cross.
In these published comparative animal studies, Fibrin Adhesive
STat®, or FAST® dressing has proven to be functionally
superior to commercially available products in significantly
reducing blood loss. The FAST® dressing contains large
quantities of the human blood clotting proteins fibrinogen,
thrombin, and Factor XIII in a dry form. Once in contact with the
wound, the components in the FAST® dressing are instantly
activated to form a fibrin clot similar to that which results from
the body’s own clotting process.
Last month STB® announced that it had completed a successful
pre-Investigational New Drug (pre-IND) submission to the U.S.
Food and Drug Administration (FDA).
“This additional funding will accelerate the remaining pre-IND
development work and animal studies for the FAST® dressing
already underway,” said Richard Moscarello, CEO of STB®. “We
appreciate the government’s continued support for this product
which soon will be translated into s
‘/>”/>
